Patents by Inventor John Goodchild
John Goodchild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6984729Abstract: The present invention discloses synthetic oligonucleotides complementary to contiguous and noncontiguous regions of the HBV RNA. Also disclosed are methods and kits for inhibiting the replication and expression of HBV, and for treating HBV infections and associated conditions.Type: GrantFiled: July 28, 1997Date of Patent: January 10, 2006Assignee: Hybridon, Inc.Inventors: Bruce L. Frank, Peter C. Roberts, John Goodchild, J. Charles Craig, John S. Mills, Andrew Slade, Robert E. Kilkuskie, Noel A. Roberts, Raymond Jupp
-
Publication number: 20030191078Abstract: Inhibition of replication of an infectious agent, gene expression of an infectious agent, or both, by administration of an oligonucleotide complementary to highly conserved regions of the infectious agent is described.Type: ApplicationFiled: November 12, 2002Publication date: October 9, 2003Applicant: Hybridon, Inc.Inventors: John Goodchild, Paul C. Zamecnik, Sudhir Agrawal
-
Publication number: 20030186911Abstract: Inhibition of replication of an infectious agent, gene expression of an infectious agent, or both, by administration of an oligonucleotide complementary to highly conserved regions of the infectious agent is described. Inhibition of replication of a virus, gene expression of a virus, or both, by administration of an oligonucleotide complementary to highly conserved regions of the virus is also described.Type: ApplicationFiled: November 12, 2002Publication date: October 2, 2003Applicant: Hybridon, Inc.Inventors: John Goodchild, Paul C. Zamecnik, Sudhir Agrawal
-
Patent number: 6573072Abstract: The present invention provides methods for increasing ribozyme catalytic activity without reducing specificity, which methods comprise contacting an RNA molecule with a ribozyme having a flanking sequence modified to contain 2′-O-substituted nucleotides. The invention also provides ribozymes comprising a flanking sequence modified to contain 2′-O-substituted nucleotides. In addition, the invention provides methods for increasing ribozyme catalytic activity comprising contacting an RNA molecule with a ribozyme having a flanking sequence modified to contain a 2′-O-substituted nucleotide and a facilitator oligonucleotide. The present invention further provides compositions comprising a ribozyme having modified flanking sequences and an effective amount of a facilitator oligonucleotide.Type: GrantFiled: October 13, 2000Date of Patent: June 3, 2003Assignee: University of Massachusetts WorcesterInventor: John Goodchild
-
Publication number: 20030055240Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.Type: ApplicationFiled: May 1, 2002Publication date: March 20, 2003Inventors: Peter C. Roberts, Bruce L. Frank, David E. Szymkowski, John S. Mills, John Goodchild, Jia L. Wolfe, Robert E. Kilkuskie, Isobel M. Greenfield, Veronica Sullivan
-
Patent number: 6509149Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.Type: GrantFiled: June 6, 1995Date of Patent: January 21, 2003Assignee: Hybridon, Inc.Inventors: Peter C. Roberts, Bruce L. Frank, David E. Szymkowski, John S. Mills, John Goodchild, Jia L. Wolfe, Robert E. Kilkuskie, Isobel M. Greenfield, Veronica Sullivan
-
Patent number: 6458940Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.Type: GrantFiled: July 2, 1997Date of Patent: October 1, 2002Assignee: Hybridon, Inc.Inventors: Peter C. Roberts, Bruce L. Frank, David E. Szymkowski, John S. Mills, John Goodchild, Jia L. Wolfe, Robert E. Kilkuskie, Isobel M. Greenfield, Veronica Sullivan
-
Publication number: 20020081577Abstract: The present invention discloses synthetic oligonucleotides complementary to contiguous and non-contiguous regions of the HCV RNA. Also disclosed are methods and kits for inhibiting the replication of HCV, inhibiting the expression of HCV nucleic acid and protein, and for treating HCV infections.Type: ApplicationFiled: July 2, 1997Publication date: June 27, 2002Inventors: ROBERT L. KILKUSKIE, BRUCE L. FRANK, JOHN GOODCHILD, JIA L. WOLFE, PETER C. ROBERTS, HENRY A. HAMLIN, NOEL A. ROBERTS, DEBRA M. WALTHER
-
Publication number: 20020068820Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.Type: ApplicationFiled: June 6, 1995Publication date: June 6, 2002Inventors: PETER C. ROBERTS, BRUCE L. FRANK, DAVID E. SZYMKOWSKI, JOHN S. MILLS, JOHN GOODCHILD, JIA L. WOLFE, ROBERT E. KILKUSKIE, ISOBEL M. GREENFIELD, VERONICA SULLIVAN
-
Publication number: 20010010899Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.Type: ApplicationFiled: July 2, 1997Publication date: August 2, 2001Inventors: PETER C ROBERT, BRUCE L. FRANK, DAVID E. SZYMKOWSKI, JOHN S. MILLS, JOHN GOODCHILD, JIA L. WOLFE, ROBERT E. KILKUSKIE, ISOBEL M. GREENFIELD, VERONIA SULLIVAN
-
Patent number: 6204027Abstract: The present invention provides methods for increasing ribozyme catalytic activity without reducing specificity, which methods comprise contacting an RNA molecule with a ribozyme having a flanking sequence modified to contain 2′-O-substituted nucleotides. The invention also provides ribozymes comprising a flanking sequence modified to contain 2′-O-substituted nucleotides. In addition, the invention provides methods for increasing ribozyme catalytic activity comprising contacting an RNA molecule with a ribozyme having a flanking sequence modified to contain a 2′-O-substituted nucleotide and a facilitator oligonucleotide. The present invention further provides compositions comprising a ribozyme having modified flanking sequences and an effective amount of a facilitator oligonucleotide.Type: GrantFiled: December 9, 1997Date of Patent: March 20, 2001Assignee: University of Massachusetts WorcesterInventor: John Goodchild
-
Patent number: 6087484Abstract: Methods are disclosed for increasing ribozyme catalytic activity without reducing specificity, which methods comprise contacting an RNA molecule with a ribozyme and a 2'-O-substituted facilitator oligonucleotide. The present invention further provides compositions comprising a ribozyme and an effective amount of a 2'-O-methyl substituted facilitator oligonucleotide. The use of a facilitator, particularly a 2'-O-substituted facilitator, and more especially a 2'-O-methyl substituted facilitator, greatly enhances ribozyme catalytic activity, frequently making an otherwise inactive ribozyme active.Type: GrantFiled: March 18, 1997Date of Patent: July 11, 2000Assignee: University of Massachusetts WorcesterInventor: John Goodchild
-
Patent number: 5856459Abstract: The present invention discloses synthetic oligonucleotides complementary to contiguous and noncontiguous regions of the HBV RNA. Also disclosed are methods and kits for inhibiting the replication and expression of HBV, and for treating HBV infections and associated conditions.Type: GrantFiled: June 6, 1995Date of Patent: January 5, 1999Assignee: Hybridon, Inc.Inventors: Bruce L. Frank, Peter C. Roberts, John Goodchild, J. Charles Craig, John S. Mills
-
Patent number: 5700923Abstract: Disclosed is a finderon having the ability to endonucleolytically cleave a sequence of 3' to 5' linked ribonucleotides. The finderon includes a rigid linker comprising at least one non-nucleotidic unit, flanked by first and second flanking regions of at least four contiguous, covalently-linked nucleotides. At least a portion of each flanking region is complementary to a target region on a substrate RNA molecule. Also disclosed are methods of preparing and using a finderon, and kits including a finderon.Type: GrantFiled: September 29, 1994Date of Patent: December 23, 1997Assignee: Hybridon, Inc.Inventors: John Goodchild, Thomas E. Leonard
-
Patent number: 5679555Abstract: Disclosed are ribozyme analogs having the ability to endonucleolytically cleave a sequence of 3' to 5' linked ribonucleotides. The ribozyme analogs include a plurality of 3' to 5' covalently-linked nucleotides, and a rigid molecular linker having at least one non-nucleotidic molecule covalently linked to two of the nucleotides. Also disclosed are methods of preparing and utilizing the ribozyme analogs of the invention, and pharmaceutical formulations and kits containing such ribozyme analogs.Type: GrantFiled: June 7, 1995Date of Patent: October 21, 1997Assignee: Hybridon, Inc.Inventors: John Goodchild, Thomas E. Leonard
-
Patent number: 5679554Abstract: Disclosed is a finderon having the ability to endonucleolytically cleave a sequence of 3' to 5' linked ribonucleotides. The finderon includes a rigid linker comprising at least one non-nucleotidic unit, flanked by first and second flanking regions of at least four contiguous, covalently-linked nucleotides. At least a portion of each flanking region is complementary to a target region on a substrate RNA molecule. Also disclosed are methods of preparing and using a finderon, and kits including a finderon.Type: GrantFiled: June 7, 1995Date of Patent: October 21, 1997Assignee: Hybridon, Inc.Inventors: John Goodchild, Thomas E. Leonard
-
Patent number: 5650502Abstract: Disclosed are ribozyme analogs having the ability to endonucleolytically cleave a sequence of 3' to 5' linked ribonucleotides. The ribozyme analogs include a plurality of 3' to 5' covalently-linked nucleotides, and a rigid molecular linker having at least one non-nucleotidic molecule covalently linked to two of the nucleotides. Also disclosed are methods of preparing and utilizing the ribozyme analogs of the invention, and pharmaceutical formulations and kits containing such ribozyme analogs.Type: GrantFiled: November 9, 1994Date of Patent: July 22, 1997Assignee: Hybridon, Inc.Inventors: John Goodchild, Thomas E. Leonard
-
Patent number: 5646021Abstract: Disclosed is a finderon having the ability to endonucleolytically cleave a sequence of 3' to 5' linked ribonucleotides. The finderon includes a rigid linker comprising at least one non-nucleotidic unit, flanked by first and second flanking regions of at least four contiguous, covalently-linked nucleotides. At least a portion of each flanking region is complementary to a target region on a substrate RNA molecule. Also disclosed are methods of preparing and using a finderon, and kits including a finderon.Type: GrantFiled: June 7, 1995Date of Patent: July 8, 1997Assignee: Hybridon, Inc.Inventors: John Goodchild, Thomas E. Leonard
-
Patent number: 5627055Abstract: Disclosed is a finderon having the ability to endonucleolytically cleave a sequence of 3' to 5' linked ribonucleotides. The finderon includes a rigid linker comprising at least one non-nucleotidic unit, flanked by first and second flanking regions of at least four contiguous, covalently-linked nucleotides. At least a portion of each flanking region is complementary to a target region on a substrate RNA molecule. Also disclosed are methods of preparing and using a finderon, and kits including a finderon.Type: GrantFiled: June 7, 1995Date of Patent: May 6, 1997Assignee: Hybridon, Inc.Inventors: John Goodchild, Thomas E. Leonard
-
Patent number: 5612469Abstract: Methods are disclosed for increasing ribozyme catalytic activity without reducing specificity, which methods comprise contacting an RNA molecule with a ribozyme and a facilitator oligonucleotide.The present invention further provides compositions comprising a ribozyme and an effective amount of a facilitator oligonucleotide.Type: GrantFiled: May 1, 1995Date of Patent: March 18, 1997Assignee: Worcester Foundation for Experimental BiologyInventor: John Goodchild